Αρχική World News Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients with...

Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients with HER2-positive Metastatic Breast Cancer

Drug–related interstitial lung disease (ILD) occurred in less than 16% of patients with HER2-positive metastatic breast cancer following treatment with trastuzumab deruxtecan (T-DXd) at the approved dose (5.4 mg/kg), and the majority of these cases were Grade 1 or 2 according to findings presented at the ESMO Breast Cancer Virtual Congress 2021, held 5 to 8 May.

Lead author Charles A. Powell of the Pulmonary Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, USA said that the phase II DESTINY-Breast01 study demonstrated strong efficacy of T-DXd in patients with pre-treated HER2-positive metastatic breast cancer. The study demonstrated an objective response rate of 61.4%, and median progression-free survival of 19.4 months.

In addition, a manageable safety profile was shown, which supported approval in the US, Japan, EU and UK for the treatment of patients with HER2-positive metastatic breast cancer that has progressed on ≥2 anti-HER2 therapies.

However, ILD remains an important identified risk with T-DXd. Dr. Powell and co-investigators set out to determine the occurrence of ILD in this patient population. They used data from patients with HER2-positive metastatic breast cancer treated with T-DXd monotherapy at 5.4 mg/kg every 3 weeks from August 2015 to June 2020; of these 61 patients participated in two phase I studies (DS8201-A-J101 [NCT02564900], DS8201-A-A104 [NCT03383692]) and 184 patients were in the phase II DESTINY-Breast01 study (NCT03248492).

Imaging and clinical data from baseline through the time of potential ILD case were retrospectively reviewed by an independent adjudication committee.

The investigators reported only ILD events that were adjudicated as drug related

This analysis included data from 245 patients with heavily pretreated HER2-positive metastatic breast cancer who received T-DXd for a median 9.7 months (range, 0.7 to 40.3 months).

During treatment, 38 (15.5%) patients experienced an ILD event that was adjudicated as drug related. Thirty (12.2%) were Grade 1 or 2 events. Grade 3 and Grade 4 ILD events were reported in one (0.4%) patient each. Six (2.4%) patients died due to a Grade 5 ILD event. Of patients with ILD, most (79%) experienced Grade 1 or 2 events.

Most of the ILD events occurred within the first 12 months of treatment. The median time to first ILD event was 5.6 (range, 1.1 to 20.8) months, with 97% of patients experiencing the first onset of ILD prior to 12 months. Forty-two percent of patients were treated for ≥12 months.


Time to event analysis for drug–related interstitial lung disease onset.

© Charles A. Powell.

The risk of patients having a new any grade ILD event beyond 12 months after treatment initiation was low, with a conditional probability of 1.8%.

In 27 of 44 (61.4%) events, the adjudication committee assessed the onset of ILD as being earlier than that reported by investigators (median difference, 52 days; range, 1 to 288 days). A summary on the use of steroids to manage ILD was also reported.


The investigators concluded that when T-DXd was administered at the approved dose (5.4mg/kg), most ILD events were low grade and occurred in the first 12 months. They added that the risk decreased after 12 months from the start of treatment, suggesting no cumulative toxicity.

It was noted that the adjudication committee assessed the onset of ILD as being earlier than the investigators in the majority of cases, which highlights the need for close monitoring that allows for earlier identification and effective management of ILD using updated guidelines.

They stated that additional follow-up is needed to confirm these findings.

Funding from AstraZeneca Pharmaceuticals LP was disclosed for this analysis. In March 2019, AstraZeneca and Daiichi Sankyo entered into a global development and commercialisation collaboration agreement for trastuzumab deruxtecan.


92O – Powell CA, Modi S, Iwata H, et al. Analysis of study drug–related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd). ESMO Breast Cancer Virtual Congress 2021 (5-8 May).



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Foodie Friday: It’s Berry Season!

July is National Berry Month! If berries aren’t part of your daily diet, now is the perfect time to start eating more of these...

No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia

On 23 July 2021, the European Medicines Agency (EMA) announced that its Committee for Medicinal Products for Human Use (CHMP) has endorsed findings of...

Expecting Mom Finds Pregnant Stray Cat And Gives Her A Home

A woman was 9 months pregnant when she found a pregnant stray cat. Unable to bear the thought of the fellow mom giving birth...

3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout

Karen Warner Schueler is the president of her own executive coaching firm and author of The Sudden Caregiver: A Roadmap for Resilient Caregiving. For...

FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL

July 29, 2021, by NCI Staff FDA's approval of Rylaze is expected to help address a long-running shortage of the drug Erwinia asparaginase for kids...

EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib

On 22 July 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...